<International Circulation>: You mentioned CRP do you think surrogate biomarkers like these have any application in terms of real clinical practice? Professor Ralph Brindis: We are certainly learning a lot from these surrogate biomarkers. We heard a terrific talk today which highlighted the advantages and disadvantages on the use of these biomarkers to assess the efficacy of medication in other words how they can help us but also in some respects mislead us. So, we must put these biomarkers in proper context of clinical trials looking at outcomes to appreciate their tr
上一页 [1] [2] [3]
网友评论仅供其表达个人看法,并不表明国际循环同意其观点或证实其描述。 发表评论需登陆